Nomura Reaffirms “Buy” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Nomura reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report report published on Tuesday morning, AnalystRatings.com reports. Nomura currently has a $37.00 target price on the stock.

“Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future.”,” the firm’s analyst commented.

A number of other equities research analysts have also recently commented on VYGR. Wedbush raised their target price on Voyager Therapeutics from $27.00 to $36.00 and gave the company an outperform rating in a research report on Tuesday, June 18th. Morgan Stanley raised their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the company an equal weight rating in a research report on Friday, July 12th. BidaskClub cut Voyager Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 7th. Finally, HC Wainwright restated a buy rating and set a $26.00 target price on shares of Voyager Therapeutics in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Voyager Therapeutics presently has a consensus rating of Buy and a consensus target price of $27.50.

NASDAQ:VYGR opened at $21.43 on Tuesday. Voyager Therapeutics has a 52 week low of $7.76 and a 52 week high of $28.79. The stock has a market capitalization of $760.57 million, a PE ratio of -7.79 and a beta of 2.55. The stock’s 50-day moving average price is $23.91 and its 200-day moving average price is $20.68.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Friday, August 9th. The company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $1.17. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. The firm had revenue of $46.09 million for the quarter, compared to analysts’ expectations of $5.25 million. As a group, equities research analysts expect that Voyager Therapeutics will post -2.44 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC acquired a new stake in Voyager Therapeutics in the 2nd quarter worth about $27,000. NumerixS Investment Technologies Inc acquired a new stake in Voyager Therapeutics in the 2nd quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Voyager Therapeutics by 371.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,126 shares of the company’s stock worth $58,000 after buying an additional 1,675 shares during the last quarter. Bank of Montreal Can boosted its holdings in Voyager Therapeutics by 244.1% in the 2nd quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock worth $76,000 after buying an additional 1,994 shares during the last quarter. Finally, SG3 Management LLC acquired a new stake in Voyager Therapeutics in the 1st quarter worth about $57,000. Institutional investors own 73.92% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Read More: No Load Funds

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.